Nutra Pharma to Seek GSA Certification, Will Market Military Strength Nyloxin to Governmental Agencies and the DoD
22 April 2014 - 10:30PM
Marketwired
Nutra Pharma to Seek GSA Certification, Will Market Military
Strength Nyloxin to Governmental Agencies and the DoD
Nutra Pharma Is Announcing That They Are in the Process of
Completing Their GSA Contract Application to Begin Marketing and
Distribution of the Company's Over-the-Counter (OTC) Pain Reliever,
Nyloxin(R), to the US Military and Other Governmental Agencies
CORAL SPRINGS, FL--(Marketwired - Apr 22, 2014) - Nutra Pharma
Corp. (OTCQB: NPHC), a biotechnology company that is developing
treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple
Sclerosis (MS), is announcing that they are seeking GSA (Government
Services Administration) Certification in order to supply a
specially formulated Military Strength Nyloxin® to the Department
of Defense (DoD) and Veterans Affairs Hospitals (VA).
"With the nation focused on the treatment of chronic pain,
especially for returning military veterans, our specially
formulated version of Nyloxin should go a long way to effectively
managing chronic pain symptoms for many of our wounded warriors,"
stated Rik J Deitsch, CEO of Nutra Pharma. "By securing a GSA-MAS
contract, we can effectively distribute our products directly to
various agencies and health departments at set government pricing,"
he continued. "It is our plan to complete the GSA application
process and begin actively marketing Nyloxin, Nyloxin Extra
Strength and Nyloxin Military Strength through the GSA in the next
few months," he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin®
is currently available in the United States as an oral spray for
treating back pain, neck aches, headaches, joint pain, migraines,
and neuralgia, and as a topical gel for treating joint pain, neck
pain, arthritis pain, and pain from repetitive stress. In addition
to its everyday strength formulation, Nyloxin® is also offered in
an extra strength formula for more advanced, Stage 3, chronic pain.
Nutra Pharma announced last year that they would be launching their
strongest version of the product, Nyloxin® Military Strength, for
distribution to the US Military and other Governmental
Agencies.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin®.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.net
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. Marketing through the GSA should not
be construed as an indication in any way whatsoever of the future
value of the Company's common stock or its financial value. The
Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647
IR@nutrapharma.com
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Jan 2024 to Jan 2025
